Metastatic Renal Cell Cancer Clinical Trial
Official title:
An Open-Label, Multi-Center, Expanded Access Study of RAD001 in Patients With Metastatic Carcinoma of the Kidney Who Are Intolerant of or Have Progressed Despite Any AvailableVascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
This expanded access study is designed to provide RAD001 to patients with MRCC who are without satisfactory treatment alternatives, until RAD001 becomes commercially available.
n/a
N/A
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02664883 -
Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer
|
||
| Completed |
NCT03229278 -
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
|
Phase 1 | |
| Completed |
NCT01462214 -
Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT02555748 -
Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma
|
Phase 4 | |
| Completed |
NCT02899078 -
Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT00670748 -
Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer
|
Phase 2 | |
| Completed |
NCT01829841 -
A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01767636 -
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
|
Phase 2 | |
| Recruiting |
NCT02542202 -
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer
|
N/A | |
| Completed |
NCT02626130 -
Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer
|
Early Phase 1 | |
| Completed |
NCT01522820 -
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT01590069 -
Aerosolized Aldesleukin in Treating Patients With Lung Metastases
|
Phase 1 | |
| Recruiting |
NCT01884961 -
Radiotherapy as an Immunological Booster in Patients With Metastatic Melanoma or Renal Cell Carcinoma Treated With High-dose Interleukin-2
|
Phase 2 | |
| Completed |
NCT02599194 -
18F-FSPG PET/CT for Cancer Patients on Therapy
|
Phase 2 | |
| Completed |
NCT01246843 -
Evaluation of Cognitive Function of Patients With Sunitinib or Sorafenib
|
N/A | |
| Completed |
NCT01258348 -
A Phase 1b Trial in Patients With Renal Cell Cancer
|
Phase 1 | |
| Completed |
NCT00428220 -
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
|
N/A | |
| Active, not recruiting |
NCT03092856 -
Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
|
Phase 2 | |
| Completed |
NCT02843607 -
Combination of Cryosurgery and NK Immunotherapy for Advanced Kidney Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT02318771 -
Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer
|
Phase 1 |